Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14445MR)

This product GTTS-WQ14445MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14445MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7778MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GS-5745
GTTS-WQ14459MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ2748MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ11582MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MGAH-22
GTTS-WQ9156MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ2315MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ5128MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CAN-04
GTTS-WQ12465MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NKTR-214
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW